1 Report Overview
1.1 Global Antisense Oligonucleotide Therapeutics Market Overview
1.2 Study Goals and Objectives
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Data Sources
1.8 Market Evaluation & Forecasting Methodology
1.9 COIVD-19 Impact Recovery Pattern Analysis
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2 Executive Summary
2.1 Chemical modifications of antisense oligonucleotides (ASO)
3 Antisense Oligonucleotide Therapeutics Products and Technology Overview
3.1 Introduction to Nucleic Acid Technologies
3.2 Genetic Variation and Analysis
3.2.1 Sequencing Technologies
3.2.2 Sanger Sequencing
3.3 Next-generation Sequencing
3.3.1 DNA Write (Synthesis) Technologies
3.4 PCR-Based Approaches
3.5 Solid-Phase-Based Approaches
3.5.1 Microfluidic Technologies
3.5.2 DNA Microarrays
3.6 Gene Editing Technologies
3.7 CRISPR Enzyme Technologies
3.8 Gene Editing Delivery Technologies
3.9 Viral Delivery Technologies
4 DNA Read, Write and Edit Initiatives
4.1 Initiatives
4.2 American Gut Consortium
4.2.1 BabySeq
4.2.2 Blood Profiling Atlas
4.2.3 Cancer-ID
4.2.4 Cancer Moon Shots Program
4.2.5 China Precision Medicine Initiative
4.2.6 Clinical Genome Resource
4.2.7 Epigenetics for Females Personalized Cancer Care
4.2.8 France Genomic Medicine Plan
4.2.9 Friends of Cancer Research Project
4.3 Gene Therapy Initiative
4.3.1 Immunomonitor Consortium
4.3.2 Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
4.3.3 Laboratory for Genomics Research
4.3.4 Lung Cancer Master Protocol Project
4.3.5 Matchmaker Exchange
4.3.6 Medical Genome Initiative
4.3.7 Million Veteran Program
4.3.8 Molecular Integration in Neurological Diagnosis
4.3.9 MedSeq
4.4 National Microbiome Initiative
4.4.1 Next-generation Single Cell Analysis Program
4.4.2 Precision Medicine Initiative
4.4.3 Prospective Registry of Multiple Testing
4.4.4 Quality Assurance Initiative Pathology Project
4.4.5 Somatic Cell Genome Editing Program
4.4.6 Trans Omics for Precision Medicine Initiative
4.4.7 Population Sequencing Programs
5 Market Dynamics
5.1 Overview
5.2 SWOT Analysis
5.3 Drivers of Antisense Oligonucleotide Therapeutics Market
5.3.1 High Unmet Medical Need
5.3.2 Positive Investment Environment
5.3.3 Strong Pipeline
5.3.4 Acceptance from Regulatory Authorities
5.4 Challenges for Antisense Oligonucleotide Therapeutics Market
5.4.1 Lack of Regulatory Guidance
5.4.2 Need for Skilled Labor
5.5 Opportunities for Antisense Oligonucleotide Therapeutics Market
5.5.1 Emerging Markets
5.5.2 Development of Better Diagnostic Methods
5.5.3 Acquisitions and Partnerships
5.6 Threats to the Antisense Oligonucleotide Therapeutics Market
5.6.1 New Government Regulations
5.6.2 Stiff Competition in the Global Market
5.7 Porter’s Five Forces Analysis of the Antisense Oligonucleotide Therapeutics Market
5.7.1 Bargaining Power Of Suppliers-Low
5.7.2 Bargaining Power of Buyers-High
5.7.3 Intensity of Competition-High
5.7.4 Threat of Substitute Products-High
5.7.5 Threat of New Entrants-High
6 Global Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
6.1 Global Market Outlook
6.1.1 FDA Approved Formulations
6.2 Global Market Size Estimation and Forecast
6.2.1 Pre-COVID-19 Market Analysis
6.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.3 Global Market Breakdown by Region
6.3.1 Pre-COVID-19 Market Analysis
6.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.4 Global Market Breakdown by Therapeutic Area
6.4.1 Antisense Oligonucleotide Based Therapy in Neuromuscular Disorders
6.4.2 Pre-COVID-19 Market Analysis
6.4.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.5 Global Market Breakdown by Route of Administration
6.5.1 Enhanced Stabilization Chemistry-Based Delivery
6.5.2 Nanoformulation-Based Delivery
6.5.3 Lipid-Based Delivery Systems
6.5.4 Pre-COVID-19 Market Analysis
6.5.5 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
6.6 Global Market Breakdown by Type
6.6.1 Antisense Therapy For Cancer
6.6.2 Antisense Therapy For Cardiovascular Diseases
6.6.3 Antisense Therapy For Inflammation And Autoimmune Diseases
6.6.4 Antisense Therapy In Neurological Disorders
6.6.5 Antisense Therapy For Infectious Diseases
6.6.6 Pre-COVID-19 Market Analysis
6.6.7 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7 North America Antisense Oligonucleotide Therapeutics Market Outlook
7.1 North America Market Overview
7.2 North America Market Size Estimation and Forecast
7.2.1 Pre-COVID-19 Market Analysis
7.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.3 North America Market Breakdown by Country
7.3.1 Pre-COVID-19 Market Analysis
7.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.4 North America Market Breakdown by Therapeutic Area
7.4.1 Pre-COVID-19 Market Analysis
7.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.5 North America Market Breakdwon by Route of Administration
7.5.1 Pre-COVID-19 Market Analysis
7.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.6 North America Market Breakdown by Type
7.6.1 Pre-COVID-19 Market Analysis
7.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.7 US Antisense Oligonucleotide Therapeutics Market Outlook
7.7.1 Country Market Overview
7.7.2 Pre-COVID-19 Market Analysis
7.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
7.8 Canada Antisense Oligonucleotide Therapeutics Market Outlook
7.8.1 Country Market Overivew
7.8.2 Pre-COVID-19 Market Analysis
7.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8 Europe Antisense Oligonucleotide Therapeutics Market Outlook
8.1 Europe Market Overview
8.2 Europe Market Size Estimation and Forecast
8.2.1 Pre-COVID-19 Market Analysis
8.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.3 Europe Market Breakdown by Country
8.3.1 Pre-COVID-19 Market Analysis
8.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.4 Europe Market Breakdown by Therapeutic Area
8.4.1 Pre-COVID-19 Market Analysis
8.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.5 Europe Market Breakdwon by Route of Administration
8.5.1 Pre-COVID-19 Market Analysis
8.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.6 Europe Market Breakdown by Type
8.6.1 Pre-COVID-19 Market Analysis
8.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.7 Germany Antisense Oligonucleotide Therapeutics Market Outlook
8.7.1 Country Overview
8.7.2 Pre-COVID-19 Market Analysis
8.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.8 UK Antisense Oligonucleotide Therapeutics Market Outlook
8.8.1 Country Market Overview
8.8.2 Pre-COVID-19 Market Analysis
8.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.9 France Antisense Oligonucleotide Therapeutics Market Outlook
8.9.1 Country Market Overview
8.9.2 Pre-COVID-19 Market Analysis
8.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.10 Italy Antisense Oligonucleotide Therapeutics Market Outlook
8.10.1 Country Market Overview
8.10.2 Pre-COVID-19 Market Analysis
8.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.11 Spain Antisense Oligonucleotide Therapeutics Market Outlook
8.11.1 Country Market Overview
8.11.2 Pre-COVID-19 Market Analysis
8.11.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
8.12 Rest of Europe Antisense Oligonucleotide Therapeutics Market Outlook
8.12.1 Pre-COVID-19 Market Analysis
8.12.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9 Asia-Pacific Antisense Oligonucleotide Therapeutics Market Outlook
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market Size Estimation and Forecast
9.2.1 Pre-COVID-19 Market Analysis
9.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.3 Asia-Pacific Market Breakdown by Country
9.3.1 Pre-COVID-19 Market Analysis
9.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.4 Asia-Pacific Market Breakdown by Therapeutic Area
9.4.1 Pre-COVID-19 Market Analysis
9.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.5 Asia-Pacific Market Breakdwon by Route of Administration
9.5.1 Pre-COVID-19 Market Analysis
9.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.6 Asia-Pacific Market Breakdown by Type
9.6.1 Pre-COVID-19 Market Analysis
9.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.7 China Antisense Oligonucleotide Therapeutics Market Outlook
9.7.1 Country Market Overview
9.7.2 Pre-COVID-19 Market Analysis
9.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.8 India Antisense Oligonucleotide Therapeutics Market Outlook
9.8.1 Country Market Overview
9.8.2 Pre-COVID-19 Market Analysis
9.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.9 Japan Antisense Oligonucleotide Therapeutics Market Outlook
9.9.1 Country Market Overview
9.9.2 Pre-COVID-19 Market Analysis
9.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.10 South Korea Antisense Oligonucleotide Therapeutics Market Outlook
9.10.1 Country Market Overview
9.10.2 Pre-COVID-19 Market Analysis
9.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.11 Australia Antisense Oligonucleotide Therapeutics Market Outlook
9.11.1 Pre-COVID-19 Market Analysis
9.11.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
9.12 Rest of Asia-Pacific Antisense Oligonucleotide Therapeutics Market Outlook
9.12.1 Pre-COVID-19 Market Analysis
9.12.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10 Latin America, Middle East & Africa Antisense Oligonucleotide Therapeutics Market Outlook
10.1 LAMEA Market Overview
10.2 LAMEA Market Size Estimation and Forecast
10.2.1 Pre-COVID-19 Market Analysis
10.2.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.3 LAMEA Market Breakdown by Country
10.3.1 Pre-COVID-19 Market Analysis
10.3.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.4 LAMEA Market Breakdown by Therapeutic Area
10.4.1 Pre-COVID-19 Market Analysis
10.4.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.5 LAMEA Market Breakdwon by Route of Administration
10.5.1 Pre-COVID-19 Market Analysis
10.5.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.6 LAMEA Market Breakdown by Type
10.6.1 Pre-COVID-19 Market Analysis
10.6.2 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.7 Brazil Antisense Oligonucleotide Therapeutics Market Outlook
10.7.1 Country Market Overview
10.7.2 Pre-COVID-19 Market Analysis
10.7.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.8 Saudi Arabia Antisense Oligonucleotide Therapeutics Market Outlook
10.8.1 Country Market Overview
10.8.2 Pre-COVID-19 Market Analysis
10.8.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.9 South Africa Antisense Oligonucleotide Therapeutics Market Outlook
10.9.1 Country Market Overview
10.9.2 Pre-COVID-19 Market Analysis
10.9.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.10 Mexico Antisense Oligonucleotide Therapeutics Market Outlook
10.10.1 Country Market Overview
10.10.2 Pre-COVID-19 Market Analysis
10.10.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.11 UAE Antisense Oligonucleotide Therapeutics Market Outlook
10.11.1 Country Market Overview
10.11.2 Pre-COVID-19 Market Analysis
10.11.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
10.12 Rest of LAMEA Antisense Oligonucleotide Therapeutics Market Outlook
10.12.1 Market Overview
10.12.2 Pre-COVID-19 Market Analysis
10.12.3 Post COVID-19 Market Analysis (V, W, U, L Shaped Recovery Scenarios)
11 Potential Drug Candidates in Clinical Trials
11.1 Tominersen
12 Leading Company Profiles
12.1 Ionis Pharmaceuticals, Inc
12.1.1 Company Snapshot
12.1.2 Company Overview
12.1.3 Company Financial Profile
12.1.4 Company Product Benchmarking
12.1.5 Company Recent Developments
12.2 Sarpeta Therapeutics Inc.
12.2.1 Company Snapshot
12.2.2 Company Overview
12.2.3 Company Financial Profile
12.2.4 Company Product Benchmarking
12.2.5 Company Recent Developments
12.3 Biogen Inc
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Company Financial Profile
12.3.4 Company Product Benchmarking
12.3.5 Company Recent Developments
12.4 Alnylam Pharmaceuticals, Inc
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Company Financial Profile
12.4.4 Company Product Benchmarking
12.4.5 Company Recent Developments
12.5 Antisense Therapeutics Limited
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Company Financial Profile
12.5.4 Company Product Benchmarking
12.5.5 Company Recent Developments
12.6 Arrowhead Pharmaceuticals Inc.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Company Financial Profile
12.6.4 Company Product Benchmarking
12.6.5 Company Recent Developments
12.7 Enzon Pharmaceuticals, Inc.
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Company Financial Profile
12.7.4 Company Product Benchmarking
12.7.5 Company Recent Developments
12.8 Bio-Path Holdings, Inc.
12.8.1 Company Snapshot
12.8.2 Company Overview
12.8.3 Company Financial Profile
12.8.4 Company Product Benchmarking
12.8.5 Company Recent Developments
12.9 GlaxoSmithKline PLC
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Company Financial Profile
12.9.4 Company Product Benchmarking
12.9.5 Company Recent Developments
12.10 Geron Corporation (Geron)
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Company Financial Profile
12.10.4 Company Product Benchmarking
12.10.5 Company Recent Developments
13 Conclusion & Recommendations
13.1 Recommendations
14 Glossary
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/